A large study finds that ivermectin does not reduce risk of Covid-19 hospitalization.
The researchers shared these findings in August during an online conference. The National Institutes of Health hosted the presentation, but the full dataset has not yet been published in the New England Journal of Medicine.
“Now that people can dive into the details and data. We hope this will move most doctors away from ivermectin and other treatments,” said Dr. David Bulwer, an infectious disease expert at the University of Minnesota.
For decades, ivermectin has been widely used to treat parasitic infections clinical research, whose data was released on Wednesday, was much more extensive.
Brazilian researchers provided the drug to 679 patients over three days from March to August 2021 for double-blind treatment. Neither patients nor medical staff knew if any particular patient received a Covid drug or a placebo.
The results were precise: Taking ivermectin did not reduce the risk of hospitalization for Covid patients.
The researchers focused on different volunteers to see if they got benefits that others didn’t. For example, it is possible that ivermectin only works if taken early in the infection. But volunteers who took ivermectin in the first three days. After testing positive for coronavirus had worse results than those in the placebo group.
There are other large randomized trials of ivermectin involving thousands of volunteers that are still ongoing and have not yet shared their results. The National Center for the Development of Translational Sciences, part of the National Institutes of Health, ran one such project, which they followed closely. Ivermectin trial and several other medicines for Covid patients for over a year now, with no results yet.